Biomarin Pharmaceutical Inc
Change company Symbol lookup
Select an option...
BMRN Biomarin Pharmaceutical Inc
BLTS Bright Lights Acquisition Corp
STRR Star Equity Holdings Inc
BMY Bristol-Myers Squibb Co
BCTX Briacell Therapeutics Corp
ENV Envestnet Inc
CDR-B Cedar Realty Trust Inc
WCC Wesco International Inc

Health Care : Biotechnology | Mid Cap Growth
Company profile

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin 's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa) and Voxzogo (vosoritide). BioMarin's clinical development programs include Valoctocogene roxaparvovec is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A; BMN 307 is an AAV5 mediated gene therapy that is designed to normalize blood Phe concentration levels in patients with Phenylketonuria (PKU), and BMN 255 is a small-molecule therapy that is designed to treat primary hyperoxaluria type 1, a subset of chronic renal disease.

Closing Price
Day's Change
2.11 (2.68%)
B/A Size
Day's High
Day's Low

10-day average volume:



6 providers
May 18, 2022
Thiogenesis Announces Positive Results from Phase 1 Dose-Escalation Study of its Lead Compound TTI-0102

San Diego, California--(Newsfile Corp. - May 18, 2022) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing sulfur-containing therapeutics for serious pediatric diseases...(Newsfile)

May 05, 2022
BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia 2022 World Congress, May 8-11, 2022, Including Five Platform Presentations

Ongoing Clinical Development Program Represents Largest and Longest Development Program for any Gene Therapy in Hemophilia A, Demonstrates Commitment to Advancing Care for People with Hemophilia A BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today...(PR Newswire)

April 13, 2022
Lifshitz Law Firm, P.C. Announces Investigations of BioMarin Pharmaceutical Inc. (NASDAQGS: BMRN), On24, Inc. (NYSE: ONTF), Silverback Therapeutics, Inc. (NASDAQ: SBTX), and Selectquote, Inc. (NYSE: SLQT)

EQNX::TICKER_START (NYSE:ONTF),(NYSE:SLQT),(NASDAQ:BMRN),(NasdaqGM:SBTX), EQNX::TICKER_END BioMarin Pharmaceutical Inc. (NASDAQGS: BMRN) Lifshitz Law PLLC announces that a class action complaint was filed on behalf of shareholders of BioMarin...(Globe Newswire)

March 25, 2022
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating BioMarin Pharmaceutical Inc.

Wilmington, Delaware--(Newsfile Corp. - March 25, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) on behalf of stockholders.(Newsfile)

March 17, 2022
BioMarin Announces Publication in New England Journal of Medicine of One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A

New England Journal of Medicine Publishes Editorial: Prepare the Way for Hemophilia A Gene Therapy Significantly Reduced Bleeding and Factor VIII Utilization Compared to Baseline Factor VIII Prophylactic Therapy (PR Newswire)

March 04, 2022
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Ardelyx, BioMarin, Chegg, and ChemoCentryx on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors Ardelyx, Inc. (NASDAQ: ARDX), BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN), Chegg, Inc. (NYSE: CHGG), and...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.